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Abstract
 
The vascular endothelium is a critical regulator of vascular function. Diverse stimuli such as
proinflammatory cytokines and hemodynamic forces modulate endothelial phenotype and
thereby impact on the development of vascular disease states. Therefore, identification of the
regulatory factors that mediate the effects of these stimuli on endothelial function is of consid-
erable interest. Transcriptional profiling studies identified the Kruppel-like factor (KLF)2 as be-
ing inhibited by the inflammatory cytokine interleukin-1
 
 
 
 and induced by laminar shear stress
in cultured human umbilical vein endothelial cells. Overexpression of KLF2 in umbilical vein
endothelial cells robustly induced endothelial nitric oxide synthase expression and total enzy-
matic activity. In addition, KLF2 overexpression potently inhibited the induction of vascular
cell adhesion molecule-1 and endothelial adhesion molecule E-selectin in response to various
proinflammatory cytokines. Consistent with these observations, in vitro flow assays demon-
strate that T cell attachment and rolling are markedly attenuated in endothelial monolayers
transduced with KLF2. Finally, our studies implicate recruitment by KLF2 of the transcrip-
tional coactivator cyclic AMP response element–binding protein (CBP/p300) as a unifying
mechanism for these various effects. These data implicate KLF2 as a novel regulator of endo-
thelial activation in response to proinflammatory stimuli.
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Introduction
 
As the interface between blood and all tissues, the vascular
endothelium is critically involved in the biological response
to inflammation (1). Proinflammatory stimuli such as cyto-
kines induce endothelial dysfunction and confer a proadhe-
sive and prothrombotic phenotype (2, 3). Although these
events are important in certain adaptive responses such as
wound healing, sustained endothelial activation can lead to
deleterious consequences as seen in several chronic inflam-
matory disease states such as rheumatoid arthritis, inflam-
matory bowel disease, and atherosclerosis (4).
One of the initial and key events in the endothelium’s
response to inflammatory stimuli is the expression of adhe-
sion molecules such as vascular cell adhesion molecule
(VCAM)-1 and E-selectin. These proteins mediate early
leukocyte attachment and rolling on the endothelial surface
(5). Subsequent events such as firm adhesion and transmi-
gration across the endothelial lining then set the stage for a
developing inflammatory response within tissues (5). Given
the importance of these adhesion molecules in inflamma-
tion, the molecular mechanisms regulating their expression
has been the subject of considerable investigation. Several
studies have shown that the induction of VCAM-1 and
E-selectin by inflammatory stimuli occurs principally at the
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level of transcription (6, 7). Furthermore, these studies
highlight the central importance of nuclear factor 
 
 
 
B (NF-
 
 
 
B) in mediating the induction of these adhesion molecules
(6, 7, 8).
Accumulating evidence also suggests that in addition to
biochemical stimuli such as inflammatory cytokines, fluid
mechanical forces regulate key aspects of endothelial func-
tion (9). Unbranched segments of the vascular tree are ex-
posed to laminar shear stress (LSS), whereas branch points
experience disturbed/turbulent shear stress and flow rever-
sal (9). Previous studies show that LSS induces specific gene
products such as endothelial nitric oxide synthase (eNOS),
which confers antiinflammatory and antithrombotic prop-
erties to the endothelium (10, 11). In addition, eNOS is an
essential regulator of vascular reactivity and tone (12, 13).
The ability of laminar flow to induce genetic factors that
impart favorable properties to the endothelium is particu-
larly relevant in certain inflammatory disease states such as
atherosclerosis (14, 15). Indeed, atherosclerotic lesion de-
velopment is accentuated at branch points that do not ex-
perience LSS (2, 14). Interestingly, these regions also ex-
hibit increased levels of proinflammatory mediators such as
NF-
 
 
 
B and adhesion molecules such as VCAM-1 (16–18).
These observations suggest that hemodynamic forces such
as LSS may be protective against atherosclerotic disease de-
velopment (19).
Kruppel-like factors (KLFs) are a subclass of the zinc fin-
ger family of transcription factors which regulates cellular
differentiation and tissue development (20). For example,
KLF1/erythroid KLF is essential for red blood cell matura-
tion (21, 22), whereas KLF4/gut KLF regulates the differ-
entiation and maturation of dermal and gastrointestinal epi-
thelial cells (23, 24). Targeted disruption of KLF2/lung
KLF revealed an essential role in programming the quies-
cent phenotype of single-positive T cells and lung develop-
ment (25, 26). Furthermore, within the blood vessel wall
KLF2 expression is exclusively within endothelial cells, and
KLF2-null mice exhibit abnormal blood vessel formation,
resulting in embryonic hemorrhage and death (embryonic
day 12.5 [27]). Recently, KLF2 expression was shown to
be increased when cultured endothelial cells were exposed
to sustained shear stress (28). However the targets and
function of KLF2 in endothelial cell biology have not been
elucidated.
Using a transcriptional profiling approach to assess global
patterns of gene expression in cultured human umbilical
vein endothelial cells (HUVECs) exposed to different hu-
moral and biomechanical stimuli, we identified KLF2 as
being inhibited by the inflammatory cytokine IL-1
 
 
 
 and
induced by LSS. Our studies demonstrate that KLF2 in-
duces eNOS and inhibits the cytokine-mediated induction
of adhesion molecules such as E-selectin and VCAM-1.
Furthermore, we provide evidence that recruitment of the
coactivator CBP/p300 may serve as a unifying mechanism
underlying KLF2 function. Together, these observations
support a critical role for KLF2 as a “molecular switch,”
regulating critical aspects of endothelial cell function in in-
flammatory disease states.
 
Materials and Methods
 
Cell Culture and Reagents.
 
Human umbilical vein endothelial
cells, human umbilical arterial endothelial cells, human aortic
endothelial cells, and the tissue culture components were ob-
tained from Cambrex Company. Bovine aortic endothelial cells
(BAECs) were from Cell Systems and studied between passages 4
and 7. COS-7 cells were obtained from American Type Culture
Collection. Human IL-1
 
 
 
 (Calbiochem), human TNF
 
 
 
 (R&D
Systems), and LPS (Sigma-Aldrich) were used at final concentra-
tions of 2.5 ng/ml, 10 ng/ml, and 1 
 
 
 
g/ml, respectively. Anti-
bodies recognizing VCAM-1, intercellular cell adhesion mole-
cule (ICAM)-1, p50, p65, I
 
 
 
B-
 
 
 
, phospho–I
 
 
 
B-
 
 
 
, and 
 
 
 
-HA
were purchased from Santa Cruz Biotechnology, Inc., p300 anti-
body (Labvision), eNOS antibody (BD Biosciences), anti–E-selec-
tin mAb is clone H18/7 (developed in the laboratory of M.A.
Gimbrone Jr.), and anti–
 
 
 
-tubulin antibody (Sigma-Aldrich).
Adenoviral constructs were generated by the Harvard Gene
Therapy Group. The VCAM-1 promoter was a gift from W.C.
Aird (Beth Israel Deaconess Medical Center, Boston, MA). The
eNOS promoter constructs were provided by C.J. Lowen-
stein (The Johns Hopkins University School of Medicine, Balti-
more, MD) (29). The eNOS cDNA was provided by J.K. Liao
(Brigham and Women’s Hospital, Boston, MA).
 
RNA Isolation, Real-Time PCR, and Microarrays.
 
After expo-
sure to the appropriate stimulus, endothelial cells were rinsed
twice with ice cold PBS and scrapped in Trizol (GIBCO BRL).
RNA was isolated by ethanol precipitation and DNase treated
and purified on column (QIAGEN). The RNA integrity was as-
sessed by a microfluidics RNA 6000 Nano-Assay using a 2100
Bioanalyzer (Agilent Technologies). For real-time PCR, RNA
was transcribed using a MultiScribe-based RT reaction (PE Bio-
systems). PCR reactions were performed under conditions estab-
lished previously in a GeneAmp 5700 sequence detection system
(Applied Biosystems). For microarrays studies, 20 
 
 
 
g of total
RNA were used for making fluorescently labeled (Cy3 and Cy5)
cDNA probes. The probes, deposition control targets, and hu-
man Cot-1 DNA were added to the hybridization buffer (Agi-
lent) and incubated for 2 min at 98
 
 
 
C before the solution was
added to the surface of the microarrays. Hybridization to human
cDNA microarrays (Agilent) was performed for 17 h at 65
 
 
 
C. Ar-
rays were washed, dried, and scanned at 5 
 
 
 
m resolution using an
Agilent G2505A microarray scanner. The scanned images were
processed using Agilent feature extraction software. The resulting
feature intensities, background intensities, and artificial flags were
imported into Argus microarray analysis software for further data
analysis as described previously (30, 19).
 
Northern and Western Blot Analysis.
 
HUVECs were infected
with Ad-GFP (control) and Ad-KLF2 (K2) for 24 h, treated with
IL-1
 
 
 
 for 4 h, and then harvested for RNA or protein analysis.
Northern blot studies were performed as described previously
(31). Exogenous KLF2 mRNA expression was detected using a
mouse KLF2 cDNA probe, whereas exogenous protein was de-
tected using a polyclonal antibody (a gift from J. Leiden, Abbott
Laboratories, Chicago, IL). The endogenous KLF2 mRNA ex-
pression was detected using a 3
 
  
 
UTR fragment of the human
KLF2 cDNA. For eNOS inhibitor experiments, L-NNA (100
 
 
 
M–5 mM; Sigma-Aldrich) was added to the corresponding
plates 4 h before the treatment with IL-1
 
 
 
. After experimental
treatment of HUVECs, cellular protein extraction was performed
as described, and Western blot analyses were performed (32).
 
Transient Transfection Assays.
 
BAECs or COS-7 cells were
plated at a density of 5 
 
 
 
 10
 
4
 
/well in 6-well plates 1 d before
transfection. Transient transfection was performed using Fu- 
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gene™6 reagent (Roche Molecular Biochemicals) according to
instructions by the manufacturer. A total 1–2 
 
 
 
g of plasmid
DNA was used in transfections, and total DNA was always kept
constant. Cells were harvested 48 h after transfection, assayed
for luciferase activity, and normalized to total protein as ana-
lyzed by BCA kit (Pierce Chemical Co.) in each sample. In
some experiments, cells were treated with human TNF
 
 
 
 (10
ng/ml; R&D Systems) for 6 h before harvest. All transfections
were performed in triplicate for at least three independent
experiments.
 
eNOS Activity Assays.
 
eNOS enzyme activity was measured
by monitoring the conversion of L-[
 
3
 
H] arginine to L-[
 
3
 
H] cit-
rulline in labeled cells as described previously (33). Briefly, HU-
VECs were incubated in Hepes buffer (25 mM Hepes, pH 7.3,
109 mM NaCl, 5.4 mM KCl, 0.9 mM CaCl
 
2
 
, 1 mM MgSO
 
4
 
,
and 25 mM glucose) for 1 h at 37
 
 
 
C and then labeled with L-[
 
3
 
H]
arginine (10 
 
 
 
Ci/ml) and stimulated with 1 
 
 
 
M calcium iono-
phore A23187 for 10 min at 37
 
 
 
C. Immediately thereafter, cells
were washed two times with ice cold PBS containing 5 mM
EDTA and 5 mM 
 
l
 
-arginine, scraped into 2 ml of stop buffer (20
mM sodium acetate, pH 5.5, 1 mM 
 
l
 
-citrulline, 2 mM EDTA,
and 2 mM EGTA) and sonicated. Aliquots of these lysates were
withdrawn to determine total cellular protein abundance and 
 
3
 
H
incorporation. L-[
 
3
 
H] citrulline was isolated from the remaining
lysate by anion exchange chromatography with AG 50W-X8
resin (Bio-Rad Laboratories) and quantitated by liquid scintilla-
tion counting.
 
In Vitro Flow Assays.
 
HUVECs were infected for 24 h with
KLF2 or control adenoviruses that both encoded green fluores-
cence protein (GFP). The GFP and KLF2 are expressed as sepa-
rate proteins driven by a bidirectional ctyomegalovirus promoter.
Cells were then washed twice with warm PBS, trypsinized, and
resuspended in PBS containing 2% FBS. Cells in the two groups
were individually sorted based on equal levels of GFP expression
and plated on fibronectin-coated coverslips for adhesion and roll-
ing experiments. The laminar flow chamber used has been de-
scribed previously in detail (34, 35).
 
Glutathione S-Transferase Pull-Down and Coimmunoprecipitation
Assays.
 
Glutathione 
 
S
 
-transferase (GST) fusion proteins of KLF2,
ZnF, and KLF2
 
 
 
ZnF were generated using the pGEX-4T-1 vec-
tor according to manufacturer’s recommendations (Amersham Bio-
sciences). GST pull-down assays were performed as described
previously by incubating whole cell extract from COS-7 cell ex-
pressing full-length P300 or FLAG-tagged KLF2 with GST fusion
proteins containing different domains of KLF2 or P300 (a gift from
Dr. Y. Shi, Harvard Medical School, Boston, MA) (36). For co-
immunoprecipitation assays, COS-7 cells were transfected with
Flag-tagged P300, HA-tagged KLF2, or both using Fugene. The
presence of KLF2 and P300 complex was detected by immuno-
precipitation with anti-FLAG antibody and immunoblotting with
anti-HA antibody.
 
Gel Shift Studies.
 
For gel shift studies, 
 
 
 
20 
 
 
 
g of the nuclear
extract from HUVECs expressing Ad-GFP or Ad-KLF2 in the
presence or absence of IL-1
 
 
 
 was used for the gel shift assay. The
experiment was performed as described previously using the NF-
 
 
 
B binding sites from the VCAM-1 promoter (31). Electro-
phoretic mobility shift assay using GST-KLF2 (2.5 
 
 
 
g) or adeno-
virally overexpressed KLF2 were performed using the following
sequences: upper, 5
 
 
 
-GTCATGGGGGTGTGGGGGTTCCA-
GGAAAT-3
 
 
 
; lower: 5
 
 
 
-ATTTCCTGGAACCCCCACACC-
CCCATGAC-3
 
 
 
; upper (mutated) 5
 
 
 
-GTCATGGTATTTT-
AAGGGTTCCAGGAAAT-3
 
 
 
; and lower (mutated): 5
 
 
 
-ATT-
TCCTGGAACCCTTAAAATACCATGAC-3
 
 
 
.
 
Results
 
KLF2 Expression in Endothelial Cells Is Regulated by IL-1
 
 
 
and LSS.
 
To better understand how biochemical and
biomechanical stimuli modulate endothelial function, high
throughput genomic transcriptional profiling studies were
undertaken. In one set of experiments, cDNA microarray
analysis was performed using mRNA from HUVECs ex-
posed to vehicle or IL-1
 
 
 
 for various time periods. In a
second set of experiments, mRNA from HUVECs exposed
to LSS (10 dynes/cm
 
2
 
 for 24 h) was compared with static
(no flow) conditions. Results derived from the study of
 
 
 
15,000 genes identified several genes to be differentially
regulated by these two stimuli. One of these factors, KLF2,
was found to be inhibited by IL-1
 
 
 
 treatment and induced
by LSS. Using real-time PCR, we verified our transcrip-
tional profiling results. As shown in Fig. 1 A, exposure of
HUVECs to IL-1
 
 
 
 for 3 h resulted in a 4.7-fold decrease in
KLF2 expression. In contrast, KLF2 expression was in-
duced 4.5-fold in endothelial cells exposed to LSS when
compared with static (no flow) conditions (Fig. 1 B).
 
KLF2 Induces eNOS Expression and Activity.
 
Because
KLF2 was induced by LSS, we considered the possibility
that this transcription factor may regulate the expression of
certain LSS-inducible genes. Previous studies have identi-
fied several genes that are induced by LSS such as eNOS,
a central regulator of endothelial cell function (10). As
shown in Fig. 2 A, adenoviral overexpression of KLF2 re-
sulted in a marked induction of eNOS mRNA and protein
(Fig. 2 A). This effect was specific, since no induction
was observed on the expression of another LSS-inducible
gene COX-2 (not depicted). Furthermore, we consistently
noted that exogenous KLF2 (Fig. 2 A, exo-KLF2) inhib-
ited the expression of endogenous KLF2 (Fig. 2 A, endo-
KLF2), perhaps via a negative feedback mechanism.
To determine if the increase in eNOS expression trans-
lates into an increase in catalytically active protein, we as-
sayed for enzymatic activity by formation of L-[
 
3
 
H] citrul-
line from L-[
 
3
 
H] arginine (33, 37). As shown in Fig. 2 B,
endothelial cells overexpressing KLF2 (Ad-KLF2) exhib-
ited an 
 
 
 
79-fold induction of eNOS activity relative to
control overexpression (Ad-GFP). These data demonstrate
that KLF2 overexpression leads to a dramatic increase in
eNOS expression and activity.
Figure 1. KLF2 expression in
endothelial cells in response to
biochemcial and biomechanical
stimuli. (A) Inhibition of KLF2
by IL-1 . HUVECs were
treated with IL-1  (10 U/ml)
for the indicated times, and ex-
pression was assessed by Taqman
assay. *P   0.05. (B) Induction
of KLF2 by LSS. HUVEC
monolayers were exposed to
laminar flow (10 dynes/cm2) for
24 h, and the relative expression
of KLF2 was assessed by Taqman
assay. *P   0.05. 
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KLF2 Regulates the eNOS Promoter.
 
KLFs are transcrip-
tion factors that bind DNA and regulate target genes. To
understand how KLF2 can induce eNOS expression, we
assessed the effect on the eNOS promoter activity. For
these studies we used the –1.6-kB fragment of the human
eNOS promoter, which has been shown to confer expres-
sion in endothelial cells in vitro and in vivo (38–40). As
shown in Fig. 2 C (top), KLF2 transactivated the –1.6-kB
Luc eNOS promoter in COS-7 cells. This effect was spe-
cific, since two other family members (KLF6 and KLF15)
were unable to transactivate the eNOS promoter (not de-
picted). Using a series of deletion constructs, we found that
KLF2-mediated transactivation is partially reduced with
deletion from –0.73-kB Luc to –0.66-kB Luc construct
and essentially lost with further deletion with the –0.64-kB
Luc promoter. A similar marked reduction in activity was
seen in BAECs (Fig. 2 C, bottom). The ability to transacti-
vate the –0.66-kB Luc construct requires full-length KLF2,
since neither the DNA-binding domain alone (ZnF) nor
the non-DNA binding region (KLF2
 
 
 
ZnF) alone was able
to induce the eNOS promoter in both BAECs and COS
cells (Fig. 2 D).
The region between –0.66 and –0.64 kB of the eNOS
promoter contains a consensus KLF binding site. To assess
the importance of this site, the sequence was mutated in
the context of the full-length and the –0.66-kB Luc pro-
moter constructs. As shown in Fig. 2 C, mutation of this
site in the full-length promoter (–1.6-kBmut-Luc) resulted
in an 
 
 
 
66% reduction in KLF2-mediated transactivation.
Furthermore, mutation of this site within the –0.66-kB
construct (–0.66-kBmut) resulted in nearly complete loss of
KLF2-mediated transactivation. Finally, the ability of KLF2
to bind this site was verified by gel shift studies using puri-
fied GST-KLF2 (Fig. 2 E, left) and nuclear extracts from
adenovirally infected cells (Fig. 2 E, right).
 
KLF2 Inhibits IL-1
 
 
 
–mediated Induction of Adhesion Mole-
cules and T Cell Rolling and Adhesion to Endothelial Cells.
 
As shown in Fig. 1 A, KLF2 mRNA expression is inhibited
by IL-1
 
 
 
. Inflammatory cytokines are known to induce
several effects on endothelial cells, such as the expression
Figure 2. KLF2 regulates eNOS expression and promoter activity. (A)
KLF2 induces eNOS expression. HUVECs were infected with control
(Ad-GFP; control) and KLF2 adenovirus (KLF2) at 10 MOI for 24 h and
assessed for eNOS mRNA (Northern) and protein expression (Western).
Exo-KLF2 refers to exogenously expressed mouse KLF2. Endo-KLF2 re-
fers to endogenous human KLF2. (B) KLF2 induces eNOS enzymatic ac-
tivity. HUVECs were infected with indicated adenoviral constructs, and
eNOS activity was assessed by measuring the conversion of L-[3H] argi-
nine to L-[3H] citrulline. *P   0.0001. (C) Deletion and mutational analyses of eNOS promoter. Transient transfection and mutational studies identify
the KLF site between  644 and  652 as critical for KLF2-mediated induction of the eNOS promoter activity. Top graph indicate studies in COS-7,
whereas bottom graph is in BAECs. n   6–12 per group. *P   0.00005; **P   0.00001; ‡P   0.001. (D) KLF2 induction of the eNOS promoter is de-
pendent on DNA binding. Transient transfection studies performed in BAECs and COS-7 cells demonstrate that KLF2 but not mutant constructs
(DBD–DNA binding domain; ZnF–DNA binding domain alone; KLF2 ZnF–non-DNA binding domain) can induce the eNOS promoter. n   6–12
per group. *P   0.0001. (E) KLF2 binds the eNOS promoter. Probe is derived from the sequence between  644 and  652 in the eNOS promoter. Gel
shift studies were performed using GST–KLF2 fusion protein (left) and nuclear extracts from adenovirally overexpressed GFP (Ctrl) or KLF2 (right). Ar-
row denotes major retarded band, and arrowhead identifies the supershifted band using  -KLF2 antibody.SenBanerjee et al. 1309
of key adhesion molecules like VCAM-1, E-selectin, and
ICAM-1 (41, 5, 14). To determine the effect of KLF2 on
endothelial activation in response to inflammatory cyto-
kines, HUVECs were infected with Ad-GFP (control; C)
or Ad-KLF2 (K2) for 24 h, stimulated with IL-1  for an
additional 4 h, and assessed for adhesion molecule mRNA
and protein abundance. As shown in Fig. 3 A, treatment of
HUVECs with IL-1  strongly induced VCAM-1, E-selec-
tin, and ICAM-1 in both uninfected and control virus-
infected cells. In contrast, adenoviral overexpression of KLF2
(10 MOI) strongly inhibited the induction of VCAM-1
and E-selectin but not ICAM-1 mRNA (Fig. 3 A). This
effect was dose dependent, since no significant effect was
observed at a dose of 1 MOI. Consistent with these obser-
vations, KLF2 inhibited VCAM-1 and E-selectin protein
expression but did not affect ICAM-1 (Fig. 3 B). We also
found that the ability of KLF2 to inhibit adhesion molecule
expression was seen with other proinflammatory agents
such as LPS and TNF  (Fig. 3 C).
Adhesion molecules such as VCAM-1 mediate lympho-
cyte and leukocyte attachment to endothelial cells (41, 5).
To determine the functional consequence of KLF2’s effect
on adhesion molecule expression, in vitro flow assays were
performed (42, 43). HUVECs infected with Ad-GFP (Ctrl)
or Ad-KLF2 were FACS® sorted based on comparable lev-
els of GFP expression and exposed to IL-1  and incubated
with primary human T cells under flow conditions. As
shown in Fig. 3 D, HUVECs infected with control Ad-
GFP exhibited robust T cell attachment and rolling. In con-
trast, T cell attachment and rolling was markedly attenuated
in KLF2-overexpressing cells. These data demonstrate that
KLF2 can inhibit adhesion molecule expression and T cell
attachment and rolling to activated endothelial cells.
KLF2 Inhibits NF- B–mediated Activation. Previous
studies have demonstrated that NF- B is critical for the acti-
vation of both the VCAM-1 and E-selectin promoters in re-
sponse to inflammatory stimuli (44, 45, 6, 7, 8). This factor
normally exists in the cytoplasm as a heterodimer of the p50
and p65 subunits. Activation is controlled by a family of in-
hibitors termed I B that bind to NF- B dimers, thereby re-
taining the entire complex in the cytoplasm. Phosphorylation
and subsequent degradation of I B in response to inflamma-
tory cytokines liberates NF- B heterodimers, which can then
translocate to the nucleus, bind specific DNA sequences, and
thereby affect target gene expression (45).
As a first step, we assessed the effect of adenovirally ex-
pressed KLF2 (versus control virus; Fig. 4 A, right, C) on
p50, p65, I B, and phosphorylated I B levels at several time
points after IL-1  treatment. As shown in Fig. 4 A (left), we
did not observe any significant differences among the two
groups. In addition, we did not observe any effect on nu-
clear accumulation of p65 after IL-1  treatment (Fig. 4 A,
right). We next assessed if KLF2 can affect NF- B DNA
binding. Nuclear extracts were harvested from HUVECs
Figure 3. Effect of KLF2 on cytokine-mediated induction of adhesion mol-
ecules. (A) KLF2 inhibits VCAM-1 and E-selectin but not ICAM-1 mRNA.
HUVECs were infected with the adenovirus (C, Ad-GFP; K2, Ad-KLF2) at
the indicated dose, stimulated with IL-1  for 4 h, and total RNA was assessed
for adhesion molecule expression. In contrast to VCAM-1 and E-selectin, no
effect is observed on ICAM-1 expression. Exo-KLF2 refers to exogenously ex-
pressed mouse KLF2. Endo-KLF2 refers to endogenous human KLF2. (B)
KLF2 inhibits IL-1 –mediated induction of VCAM-1 and E-selectin protein
levels. Experiments were performed as described in A except cells were har-
vested for total protein and Western blot analysis was performed. (C) KLF2 in-
hibits VCAM-1 and E-selectin in response to multiple cytokines. HUVECs infected with the adenovirus at the indicated dose, stimulated with cytokine
for 4 h, and total RNA was assessed for adhesion molecule expression. (D) KLF2 inhibits IL-1 –mediated T cell attachment and rolling to endothelial
cells. HUVECs infected with the indicated adenovirus (Ctrl, Ad-GFP), stimulated with IL-1 , and then perfused with T cells under flow conditions
(0.75 dynes/cm2). *P   0.05.KLF2 in Endothelial Cells 1310
overexpressing Ad-GFP and Ad-KLF2 in the presence or
absence of IL-1  stimulation, and gel shift assays were per-
formed using a NF- B site derived from the VCAM-1 pro-
moter (6). As expected, NF- B binding was not detected in
either Ad-GFP (Ctrl) or Ad-KLF2–infected cells in the ab-
sence of cytokine treatment (not depicted). However, as
shown in Fig. 4 B (left) a DNA–protein complex is induced
in Ad-GFP cells after treatment with IL-1 , and the pres-
ence of p50 and p65 in this complex was verified by com-
petition and supershift studies. In the presence of KLF2
(right), a nearly identical binding pattern was observed.
These data suggest that KLF2’s inhibitory effect is not due
to effects on NF- B expression or DNA binding.
Previous studies have demonstrated that nitric oxide
(NO) can partially inhibit VCAM-1 and E-selectin in-
duction by inflammatory cytokines (46). To test this pos-
sibility, we pretreated cells with two eNOS inhibitors,
L-NAME and L-NNA, over a broad concentration range
(100  M–5 mM). Consistent with previous reports in the
literature, pretreatment with either inhibitor resulted in a
Figure 4. KLF2 inhibits NF- B function. (A) KLF2
does not affect expression or nuclear translocation of vari-
ous components of the NF- B pathway. HUVECs were
infected with the adenovirus (C, Ad-GFP; K2, Ad-KLF2),
stimulated with IL-1  for 30 or 60 min, and assessed for
expression of the indicated factors by Western blot analysis.
NE, nuclear extracts; Cyto, cytoplasmic extracts. (B) KLF2
does not affect NF- B binding to DNA. Nuclear extracts
were harvested from HUVECs overexpressing Ad-GFP
(control) and Ad-KLF2 (KLF2) in the presence or absence
of IL-1 . Induced NF- B band is designated by the arrow.
Specificity was verified by competition and supershift stud-
ies. (C) KLF2 inhibits TNF -mediated induction of the
VCAM-1 promoter and NF- B concatemer. Transient
transfection studies were performed in BAECs with the in-
dicated constructs. A similar degree of inhibition is seen
with KLF2 and KLF ZnF. n   6–12 per group; *P  
0.00005; **P   0.00001. (D) KLF2 inhibits p65-mediated
induction of the VCAM-1 and NF- B concatemer. Tran-
sient transfection studies were performed in COS-7 cells
with the indicated constructs. A similar degree of inhibi-
tion is seen with KLF2 and KLF ZnF.  n    6–12 per
group; *P   0.00005; **P   0.00001.SenBanerjee et al. 1311
small recovery of the KLF2-mediated inhibition of VCAM-1
and E-selectin protein expression ( 10–15%; not depicted)
(46). Thus, although the production of NO may contribute
in small part to the inhibitory effect of KLF2 on adhesion
molecule expression, NO does not account for the large
majority of KLF2’s inhibitory effect.
We next explored the effects of KLF2 on cytokine and
p65-mediated induction of the VCAM-1 promoter and an
NF- B reporter construct. As shown in Fig. 4 C, treatment
of BAECs with TNF  induced both the VCAM-1 pro-
moter and NF- B concatemer. Cotransfection with
KLF2 markedly attenuated this induction. Interestingly
cotransfection of the non-DNA binding domain of KLF2
(KLF2 ZnF) was equally effective in inhibiting promoter
activity, whereas the DNA binding domain alone was not
sufficient (Fig. 4 C). Similar results were seen in the heter-
ologous cell line, COS 7. Transfection with p65 resulted in
a robust induction of both the VCAM-1 and NF- B
promoter ( 130- and 160-fold, respectively; Fig. 4 D).
Cotransfection with KLF2 or KLF2 ZnF (but not ZnF
alone) potently inhibited p65-mediated transactivation of
the VCAM-1 promoter and NF- B concatemer. These
data suggest that KLF2-mediated inhibition of NF- B does
not require DNA-binding and is mediated via the non-
DNA binding domain.
Recruitment of the Coactivator CBP/p300 by KLF2 as a
Unifying Mechanism. The data presented above demon-
strate that KLF2 can induce eNOS and inhibit cytokine-
mediated induction of endothelial adhesion molecules. The
induction of eNOS requires DNA binding, whereas the in-
hibition of VCAM-1 does not. Furthermore, the inhibitory
effect occurs in the absence of any effect on p50/p65 ex-
pression or DNA binding. To reconcile these observations,
we considered the possibility that KLF2 may recruit away
from NF- B, a critical cofactor that is required for its func-
tion. Previous studies have demonstrated that NF- B ac-
tivity is critically modulated by several cofactors such as
p300/CBP, PCAF-1, and SRC-1, (47, 48, 8). We chose to
focus on p300/CBP, since it is essential for optimal NF-
 B–mediated transcriptional activity in endothelial cells (8).
In addition, previous studies demonstrate that the interac-
tion of other KLF family members with p300 is important
for the ability of these factors to transactivate reporter genes
(49–51). Consistent with this hypothesis, cotransfection of
Figure 5. KLF2 interacts directly with p300. (A) p300 rescues KLF2-
mediated inhibition. Transient transfection studies with the indicated plasmids
were performed in COS-7 cells. Cotransfection studies demonstrate that
p300 can rescue KLF2 and KLF ZnF-mediated inhibition of the NF- B
concatemer. n   6–12 per group. *P   0.00001; **P   0.00002. (B) KLF2
and p300 cooperate to induce the eNOS promoter. Cotransfection studies
were performed in COS-7 cells. Cotransfection of KLF2 and p300 induces eNOS promoter activity greater than either factor alone. n   6–12 per group;
*P   0.001; **P   0.0001; #P   0.05. (C) KLF2 and p300 interact. GST fusion proteins were generated for KLF2 and p300. Both KLF2 and KLF ZnF
can interact with p300 (top). Conversely, KLF2 interacts specifically with the NH2 terminus of p300. (D) KLF2 and p300 interact in cells. COS-7 cells
were transfected with HA-KLF2 and Flag-p300. Immunoprecipitation was performed using the  -Flag antibody (or isotype control) followed by West-
ern blot for KLF2 with  -HA antibody.KLF2 in Endothelial Cells 1312
CBP/p300 rescued both the KLF2 and KLF2 ZnF-medi-
ated repression of the NF- B concatemer (Fig. 5 A). Fur-
thermore, cotransfection of KLF2 (but not ZnF) and CBP/
p300 augmented eNOS promoter activity to a greater de-
gree than either factor alone (Fig. 5 B). These data suggest
that KLF2 and p300 can work in a cooperative fashion.
To determine if KLF2 and CBP/p300 interact directly,
we next performed GST pull-down and coimmunopre-
cipitation studies. As shown in Fig. 5 C (top), full-length
KLF2 (GST-KLF2) and the non-DNA binding region
(GST-KLF2 ZnF) can interact with p300. This effect is
specific, since no interaction was seen with GST alone
or the DNA-binding domain alone (GST-ZnF). Reverse
binding studies showed that KLF2 interacted with the
NH2 terminus of p300 (Fig. 5 C, bottom). This interac-
tion is specific, since no interaction was noted with GST
alone or other regions of p300 (GST-p300M and GST-
p300C). To verify that this interaction occurs in cells,
coimmunoprecipitation experiments were performed. As
shown in Fig. 5 D, KLF2 could be immunoprecipitated
from cellular extracts using an anti-Flag antibody to p300
but not with an IgG1 isotype control antibody. Together,
these data suggest that KLF2 and p300 can physically in-
teract in cells.
Discussion
The appreciation that inflammatory cytokines and fluid
mechanical forces can modulate endothelial gene pheno-
type served here as the basis for the use of transcriptional
profiling approaches to assess for global patterns of gene ex-
pression. From these studies we identified KLF2 as being
differentially regulated by IL-1  and defined LSS. We pro-
vide evidence that KLF2 overexpression regulates the
expression of key endothelial factors implicated in inflam-
matory states such as eNOS and VCAM-1/E-selectin. Fur-
thermore, we suggest that competition for rate-limiting
amounts of the coactivator p300 is the underlying mecha-
nism for these distinct effects of KLF2. As such, these stud-
ies identify KLF2 as a novel regulator of proinflammatory
endothelial activation.
Recruitment of immune cells is a critical feature com-
mon to most inflammatory disease states. This occurs
through endothelial expression of certain adhesion mole-
cules such as VCAM-1 and E-selectin (41, 5, 14, 44).
These molecules allow for the attachment of leukocytes
and lymphocytes to the blood vessel wall. Subsequently,
these cells migrate across the endothelial barrier, invade ad-
jacent tissues, and thereby sustain the inflammatory re-
sponse. In this context, our observation that KLF2 can po-
tently inhibit VCAM-1 and E-selectin expression is of
considerable interest (Fig. 3, A–C). Importantly, KLF2-
mediated inhibition is observed for several major physio-
logic proinflammatory stimuli such as IL-1 , TNF , and
LPS (Fig. 3 C). As a functional consequence, T cell adhe-
sion to an endothelial cell monolayer is impaired (Fig. 3 D).
The effect of KLF2 is specific because, in contrast to
VCAM-1 and E-selectin, no significant inhibition is seen
on ICAM-1 expression. This is an intriguing observation,
although the basis for this differential inhibition has not
been fully elucidated by our studies. Finally, our observa-
tions may be particularly relevant in the context of athero-
sclerosis. Recent studies by Dekker et al. demonstrated us-
ing normal human aortic tissue that KLF2 expression is
robust in the endothelium except at branch points where
expression is nearly absent (28). These regions are known
to be particularly susceptible to atherosclerotic lesion for-
mation and exhibit increased levels of NF- B and VCAM-1
expression in animal models of atherosclerosis (16, 17).
Our observations that KLF2 overexpression inhibits NF-
 B–mediated activation of VCAM-1 coupled with the dis-
tinct pattern of KLF2 expression within the vascular tree
support the possibility that KLF2 may contribute to the fo-
cal nature of early atherosclerotic disease.
Previous studies from several laboratories demonstrate
that LSS can confer antiinflammatory, antithrombotic, and
antiproliferative properties (10, 11). As such, our observa-
tions that laminar flow induces KLF2 led us to consider
potential targets of KLF2. Although KLF2 did not induce
some LSS-inducible factors such as COX-2 (unpublished
data), we did observe a robust induction of eNOS (Fig. 2
A). Indeed, to our knowledge the magnitude of eNOS in-
duction by KLF2 exceeds that observed by any other fac-
tor or stimulus. This enzyme is a well-established central
regulator of vascular function (52–54). Mice deficient in
eNOS are hypertensive, lack endothelium-dependent va-
sodilation, respond poorly to inflammatory challenge, and
exhibit enhanced atherosclerotic lesion formation in sus-
ceptible mouse strains (55–59, 12, 13). Therefore, the
KLF2-mediated induction of eNOS expression may have
important functional consequences in vascular health and
disease. However, despite its central importance our un-
derstanding of eNOS gene regulation remains incomplete.
Transgenic studies suggest that the proximal 1.6 kB of the
human eNOS promoter is sufficient to confer endothelial
expression in small and large blood vessels in some tissues
such as heart, brain, skeletal muscle, and aorta (40). Previ-
ous studies examining the human –1.6-kB promoter high-
light the importance of GATA and Sp1 factors for basal
eNOS expression (39). More recently, members of the
Smad family have been shown to induce eNOS expression
and promoter activity (29). Our dissection of the –1.6-kB
human eNOS promoter highlights the importance of a
KLF binding site ( 644 to  652) as critical for KLF2-
mediated induction of the eNOS promoter (Fig. 2, C and
E). Whether some of these previously identified factors may
cooperate with KLF2 has yet to be determined. However,
a cooperative interaction between KLFs and members of
the GATA family and Sp1 has been reported in other cel-
lular systems (60–63). It is also noteworthy that this KLF2
binding site lies next to an AP-1 element, which has been
implicated recently as mediating the LSS induction of the
eNOS promoter, raising the possibility that these factors
may cooperate to regulate eNOS gene expression (64). Fi-
nally, our studies do not exclude the possibility that KLF2
may also bind to regulatory regions outside of the –1.6-kBSenBanerjee et al. 1313
promoter. For example, Laumonnier et al. reported the
identification of an enhancer element in the eNOS pro-
moter located  4.9 kB upstream of the transcription start
site (65). Indeed, a potential KLF binding site is present
within this enhancer, raising the potential that KLF2 may
bind additional regions in regulating endogenous eNOS
expression.
To reconcile the ability of KLF2 to simultaneously in-
hibit VCAM-1 and induce eNOS (Fig. 3 B) we considered
several unifying hypotheses. For example, the induction of
eNOS by KLF2 may result in higher levels of NO, which
itself may confer antiinflammatory properties. Previous
studies demonstrate that NO can partially inhibit inflamma-
tory cytokine-mediated induction of endothelial adhesion
molecules such as VCAM-1 and E-selectin (46). Using two
eNOS inhibitors, we observed a mild rescue of KLF2-
mediated inhibition of VCAM-1 and E-selectin. These re-
sults are consistent with previous studies (46) but do suggest
that mechanism(s) independent of NO production account
for the vast majority of KLF2’s inhibitory effects. Importantly,
we observed that despite potent inhibition of the TNF  or
p65-mediated induction of VCAM-1 and NF- B promoter
activity (Fig. 4, C and D), no effect was observed on various
components of the NF- B pathway (Fig. 4 A) or NF- B
DNA binding (Fig. 4 B). In light of the fact that NF- B ac-
tivity is critically dependent on transcriptional coactivator
CBP/p300 (8) coupled with the observation that interaction
of KLFs with CBP/p300 augments their transcriptional ac-
tivity (50) led us to consider competition for this coactivator
as the basis for the observed effects. This mechanism has
been implicated in other systems such as the mutual antago-
nism observed between nuclear hormone receptors and AP-1
pathways (66). Indeed, overexpression of p300 was able to
rescue KLF2-mediated inhibition of the NF- B concatemer
and augmented KLF2 induction of the eNOS promoter
(Fig. 5, A and B). Conversely, NF- B is able to potently in-
hibit KLF2 promoter activity (unpublished data). These re-
sults suggest that KLF2 recruits p300 away from p65 to a
target gene such as eNOS and thereby promotes opposing
effects on endothelial gene expression.
In summary, we have identified KLF2 as a cytokine-inhib-
ited and LSS-induced transcription factor that regulates the
expression of key genes involved in the endothelial response
to inflammation. These studies support the possibility that
KLF2 may serve as an important “molecular switch” regulat-
ing important aspects of vascular physiology and pathology.
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